Drug-Eluting Coronary Stents for Left Main Coronary Artery Disease

Mid-term results and costs of coronary artery bypass vs drug-eluting stents for unprotected left main coronary artery disease.

BACKGROUND The optimal revascularization strategy for unprotected left main coronary artery (ULMCA) disease in the era of drug-eluting stents (DES) has become more controversial between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). METHODS AND RESULTS Since April 2004, 89 patients underwent CABG, including 82 (92.1%) off-pump procedures and 63 patients u...

Drug-eluting coronary-artery stents.

n engl j med 368;16 nejm.org april 18, 2013 1557 by Barbui et al., a consensus statement of which they are coauthors, contains no data addressing their assertion because, as Barbui has written elsewhere,1 there are no data implicating the baseline leukocyte count as a thrombotic risk factor in patients with polycythemia vera. Fourth, by choosing the reference by Campbell et al., they are confla...

Drug-eluting coronary artery stents.

Many advances have been made in the percutaneous treatment of coronary artery disease during the past 30 years. Although balloon angioplasty alone is still performed, the use of coronary artery stents is much more common. Approximately 40 percent of patients treated with balloon angioplasty developed restenosis, and this was reduced to roughly 30 percent with the use of bare-metal stents. Howev...

Percutaneous Coronary Intervention Using Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Stenosis

Coronary artery bypass surgery or drug eluting stent for unprotected left main coronary artery disease.

Coronary artery bypass surgery (CABG) is the treatment of choice in unprotected left main coronary artery disease (ULMCA). However drug eluting stent (DES) implantations in ULMCA have ushered a revolution in the field of percutaneous coronary interventions (PCI) for left main coronary artery (LMCA) by reducing peri-procedural mortality and incidence of major adverse cardiac events (MACE). More ...